Novartis files CAR-T in Europe in broader use than Gilead rival – pharmaphorum
pharmaphorum |
Novartis files CAR–T in Europe in broader use than Gilead rival
pharmaphorum Chimeric antigen receptor T–cell (CAR-T) therapies are one-off treatments that involve harvesting a patient’s T–cells, and genetically reprogramming them to fight cancer. Trial data so far show they offer a complete response – a complete absence of … Novartis files CAR–T therapy in EuropePharmaTimes Novartis seeks European approval for cell therapy KymriahReuters |
CBS News |
Playing God: “We are in the midst of a genetic revolution”
CBS News Dr. Emmanuelle Charpintier at the Max Planck Institute in Germany is one half of the duo that discovered CRISPR‘s gene-cutting abilities. She and her research partner, Jennifer Doudna of UC-Berkeley, manipulated a naturally occurring defense system in … |
Medgadget (blog) |
Global Stem Cell Media Market 2017 – Thermo Fisher, STEMCELL Technologies, Merck Millipore, Lonza
Medgadget (blog) The research study titled ‘Global Stem Cell Media Industry 2017′ evaluates the performance of the Stem Cell Media market the world, at present and historically, and makes future projections based on the result of the analysis. The report analyzes the … Stem Cells Market Size will Escalate Rapidly in the Near FuturesatPRnews (press release) |